SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2024-11-01 (dailysabah.com)
EU slaps Israeli generic drugmaker Teva with $500M antitrust fine
The European Commission announced Thursday it had imposed an antitrust fine exceeding 460 million euros ($500 million) on Israeli generic drugmaker Teva...
Read more
2024-10-31 (netnoticias.mx)
EU penalizes Teva for abuse of power, receives historic fine
500 million dollars for protecting patents and violating competition rules
Read more
2024-10-31 (bizportal.co.il)
The European Commission imposed a fine of half a billion euros on Teva for its conduct in the Copaxone market
According to the findings of the European Commission's investigation, Teva acted on several fronts to prevent competition in the copaxone market, even after the original patent expired
Read more
(aboutpharma.com)
Teva fined 462 million by the European Commission for obstructing a competing drug against multiple sclerosis
Abuse of dominant position: Teva's role in hindering the arrival of the glatiramer acetate generic on the European market recognized
Read more